Barish Edil to Immunotherapy
This is a "connection" page, showing publications Barish Edil has written about Immunotherapy.
Connection Strength
0.402
-
Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine. Ann Surg Oncol. 2013 Dec; 20 Suppl 3:S725-30.
Score: 0.099
-
Tumor-associated antigen expressing Listeria monocytogenes induces effective primary and memory T-cell responses against hepatic colorectal cancer metastases. Ann Surg Oncol. 2012 Jul; 19 Suppl 3:S597-607.
Score: 0.087
-
Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). Surg Today. 2010 May; 40(5):404-10.
Score: 0.079
-
Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. Sci Transl Med. 2021 07 28; 13(604).
Score: 0.043
-
Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. Clin Cancer Res. 2021 03 01; 27(5):1278-1286.
Score: 0.041
-
PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 2015 Jan; 38(1):1-11.
Score: 0.027
-
A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Ann Surg Oncol. 2014 Nov; 21(12):3931-7.
Score: 0.026